Fig. 11.

Evaluation of parameters related to NO/sGC/cGMP pathway after doxorubicin (DOXO) treatment (cumulative dose 10 mg/kg BW; one injection per week for five consecutive weeks) measured two and five weeks from the last DOXO injection in Ren-2 transgenic hypertensive rats (TGR) in comparison to control TGR (placebo-treated) groups; (A) excretion of nitric oxide metabolites (NOx) in urine; (B) excretion of cGMP in urine; (C) Left ventricular (LV) gene expression of sGC receptor unit β1 (GUCY1β1) determined by qRT-PCR; (D) LV protein expression of GUCY1β1 determined by Western Blotting; (E) Kidney gene expression of GUCY1β1 determined by qRT-PCR; F Kidney protein expression of GUCY1β1 determined by Western Blotting; P > 0.05 (NS); *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; **** P ≤ 0.0001 by one-way ANOVA with Tukey’s multiple comparisons test